Journal of Carcinogenesis
Covering Genesis to Therapeutics

Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 7s, https://carcinogenesis.com/

Optimization of Fast-Dissolving Lingual Films of Clonazepam Using Natural Polymers for Epilepsy Management

Mrityunjaya Ullagaddi[1], Jyothirmayee Devineni[2], Bhuvaneshwari Y. Rane[3*], Preeti Nitin Joshi[4], L. Jyothi Rani[5], Dhruv Maheshkumar Bhavsar[6], Sasikumar Dhanarasu[7], Ramenani Hari Babu[8],

[1]Department of Pharmacology, KLE College of Pharmacy, Rajajinagar, Bengaluru. KLE Academy of Higher Education and Research, Belagavi. 590010, Karnataka, India.

[2]Department of Pharmaceutics, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Nagarjuna Nagar, Guntur.Pin:522510.

[3]Department of Pharmaceutical Chemistry, KYDSCT'S College of Pharmacy Sakegaon Bhusawal 425201.

[4]Department of Applied Science & Humanities, Parul Institute of Engineering & Technology- Diploma Studies, Parul University Post Limda, Taluka Waghodia Vadodara Gujarat 391760.

[5]Department of Pharmaceutics, Mallareddy institute of pharmaceutical sciences, mallareddy vishwavidyapeeth, maismmaguda, Dhulappally, secunderabad,500100.

[6]Department of Pharmaceutics, Arihant School of pharmacy and bio research institute. Uvarsad cross road. Adalaj. Pin code – 382421.

[7]Department of Pharmaceutical Chemistry, College of Pharmacy, University of Hafr Al Batin, Hafr Al Batin-31991, Saudi Arabia.

[8]Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India 244001.

***Corresponding Author**

Bhuvaneshwari Y. Rane

Department of Pharmaceutical Chemistry, KYDSCT'S College of Pharmacy Sakegaon Bhusawal 425201.

Email id: ranebhuvaneshwari718@gmail.com

ABSTRACT

Epilepsy is a chronic neurological disorder that demands rapid and effective therapeutic interventions to control seizures and improve patient quality of life. Clonazepam, a benzodiazepine derivative with strong anticonvulsant properties, is widely used in epilepsy management but is limited by poor compliance, delayed onset, and variability in gastrointestinal absorption when administered as conventional oral formulations. To address these challenges, the present study focused on developing and optimizing fast-dissolving lingual films of clonazepam using natural polymers such as pullulan, guar gum, and sodium alginate. The films were prepared through solvent casting and evaluated for thickness, weight variation, folding endurance, surface pH, disintegration time, and drug content uniformity. In vitro dissolution studies demonstrated rapid drug release, with pullulan-based films exhibiting the fastest disintegration and highest release efficiency, while sodium alginate contributed to controlled release. Statistical optimization using response surface methodology identified formulations with balanced mechanical strength and rapid disintegration, ensuring reliable therapeutic performance. Surface morphology studies confirmed smooth texture and uniform drug dispersion, supporting stability and reproducibility. Comparative analysis with synthetic polymers highlighted natural polymers as sustainable, biocompatible alternatives with favorable film-forming properties and patient acceptability. The findings indicate that natural polymer-based fast-dissolving clonazepam films can provide a rapid therapeutic onset, improved compliance, and environmental benefits, making them a promising alternative for effective epilepsy management..

Keywords: *Epilepsy, Clonazepam, Fast-dissolving films, Natural polymers, Patient compliance, Drug delivery*

How to Cite: Mrityunjaya Ullagaddi, Jyothirmayee Devineni, Bhuvaneshwari Y. Rane, Preeti Nitin Joshi, L. Jyothi Rani, Dhruv Maheshkumar Bhavsar, Sasikumar Dhanarasu, Ramenani Hari Babu (2025) Optimization of Fast-Dissolving Lingual Films of Clonazepam Using Natural Polymers for Epilepsy Management, *Journal of Carcinogenesis*, *Vol.24, No.7s*, 572-586

1. INTRODUCTION

Epilepsy is one of the most prevalent neurological disorders affecting millions of people worldwide, characterized by recurrent and unpredictable seizures that significantly impair quality of life. Despite advances in antiepileptic drug therapy, a substantial proportion of patients continue to experience uncontrolled seizures or debilitating side effects from conventional treatment. Clonazepam, a benzodiazepine derivative with potent anticonvulsant properties, has long been employed in the management of epilepsy due to its ability to enhance gamma-aminobutyric acid (GABA) activity in the central nervous system (Stafstrom & Carmant, 2015). However, the therapeutic utility of clonazepam is often constrained by issues such as poor patient compliance, delayed onset of action, and variability in drug absorption associated with conventional oral dosage forms like tablets and capsules. These limitations highlight the necessity for alternative drug delivery strategies capable of overcoming pharmacokinetic and patient-related challenges while ensuring rapid therapeutic onset and improved bioavailability (Ghosh et al., 2023). In recent years, the development of fast-dissolving oral films (FDOFs) has emerged as an innovative approach in drug delivery technology, particularly for drugs that require a rapid onset of action. These films are thin, flexible, and designed to disintegrate quickly upon contact with saliva, thereby facilitating the direct release of the active pharmaceutical ingredient into the oral cavity. By bypassing the gastrointestinal tract and avoiding hepatic first-pass metabolism, fast-dissolving films can enhance systemic bioavailability, reduce dose variability, and provide faster relief from acute conditions such as epileptic seizures. The convenience of administration without the need for water, coupled with improved patient compliance in populations such as pediatric, geriatric, and dysphagic patients, further underscores the clinical potential of this delivery system (Prajapati et al., 2024; Sevinç Özakar & Özakar, 2021).

The formulation of clonazepam into a fast-dissolving lingual film is particularly relevant given the urgent need for immediate seizure control in epilepsy management. Oral films not only offer rapid drug release but also provide ease of handling, portability, and precise dosing. Moreover, their unobtrusive nature allows patients to administer medication discreetly, which is especially valuable for individuals who may experience social stigma associated with visible seizure management practices (Shirsand et al., 2009). While synthetic polymers have traditionally been employed in the fabrication of fast-dissolving films, growing attention is now being directed toward natural polymers due to their biocompatibility, biodegradability, low toxicity, and cost-effectiveness. Natural polymers such as pullulan, guar gum, and sodium alginate exhibit favorable film-forming properties and can be tailored to modulate drug release profiles. These attributes position them as promising alternatives to synthetic excipients in the design of sustainable and patient-friendly dosage forms (SB et al., 2011). The therapeutic and pharmaceutical significance of incorporating natural polymers into fast-dissolving films lies not only in their safety profile but also in their ability to influence key film characteristics. Mechanical properties such as tensile strength, folding endurance, and elasticity are crucial for ensuring film integrity during handling and storage. At the same time, parameters like surface pH, disintegration time, and dissolution rate directly affect patient acceptability and therapeutic performance. Optimizing these attributes requires a systematic formulation strategy that accounts for the interactions between drug, polymer, and excipients. By applying statistical tools such as response surface methodology and design of experiments, researchers can efficiently identify the optimal combination of formulation variables to achieve desired film properties and drug release kinetics (Douroumis, 2011; Karki et al., 2016).

Despite encouraging progress, a number of research gaps remain in the development of clonazepam-loaded fast-dissolving films. For instance, while synthetic polymer-based films have been extensively studied, comparative evaluations of natural polymer systems are limited. Furthermore, inconsistencies in disintegration and dissolution performance across different natural polymers necessitate a deeper understanding of the physicochemical mechanisms governing drug release. Addressing these gaps through well-designed experimental studies can provide valuable insights into the role of polymer type and concentration in modulating film behavior, ultimately leading to more robust and effective formulations. This knowledge is particularly critical for epilepsy management, where the unpredictability and severity of seizures demand immediate and reliable therapeutic intervention (Alberti et al., 2015; Vasilev, 2014). Another important consideration is the balance between rapid drug release and sustained therapeutic effect. Clonazepam, while effective, is associated with risks of tolerance and dependence when administered inappropriately. Therefore, optimizing film dissolution kinetics to ensure rapid onset without compromising therapeutic duration is a key challenge in formulation design. Natural polymers, with their diverse structural and functional properties, offer a unique platform for achieving this balance. For example, pullulan is known for its excellent film-forming ability and rapid solubility, while sodium alginate can provide controlled-release characteristics. Combining such polymers in suitable ratios may allow formulators to fine-tune drug release profiles according to therapeutic needs. These innovations have the potential to significantly improve patient adherence and clinical outcomes in epilepsy therapy (H.-Y. & T.-F., 2011).

The development of fast-dissolving clonazepam films also carries broader implications for the field of personalized medicine. By enabling flexible dosing, films can be tailored to meet the needs of individual patients, thereby minimizing adverse effects and maximizing therapeutic efficacy. This adaptability is particularly relevant in pediatric epilepsy, where precise dosing is crucial but often challenging with conventional tablets and liquid formulations. Moreover, the portability and discreet nature of films align well with modern lifestyle demands, reducing barriers to adherence and fostering greater

patient autonomy. Collectively, these factors highlight the promise of fast-dissolving films as a transformative dosage form in epilepsy management (Shirsand et al., 2008). In addition to clinical benefits, the utilization of natural polymers aligns with the growing emphasis on sustainable pharmaceutical practices. Synthetic polymers, while effective, often raise concerns related to environmental impact, production costs, and long-term safety. Natural polymers, derived from renewable sources, present an eco-friendly alternative that resonates with contemporary goals of green chemistry and sustainable healthcare. By prioritizing natural materials in drug delivery systems, researchers not only advance therapeutic innovation but also contribute to broader societal goals of environmental responsibility and resource conservation. This dual benefit strengthens the case for exploring natural polymers in clonazepam film development and sets the stage for further investigations into other therapeutic applications (Pires et al., 2023). The present study is motivated by the convergence of clinical need, technological innovation, and sustainable practice. It seeks to optimize the formulation of fast-dissolving lingual films of clonazepam using natural polymers through systematic experimental design and evaluation. By characterizing film properties such as thickness, weight variation, folding endurance, surface pH, disintegration time, and drug content uniformity, alongside in vitro dissolution studies, the research aims to establish a comprehensive understanding of how natural polymers influence formulation performance. Advanced statistical optimization techniques will be employed to identify the best-performing formulations, offering evidence-based guidance for future development. The ultimate objective is to create a drug delivery system that combines rapid therapeutic action, patient convenience, safety, and sustainability (Shirsand et al., 2011).

In summary, the optimization of fast-dissolving lingual films of clonazepam represents a promising strategy to address the pressing challenges of epilepsy management. By leveraging the advantages of natural polymers, the research aspires to overcome the shortcomings of conventional oral dosage forms and deliver a patient-centered, environmentally conscious solution. This introduction outlines the rationale, significance, and objectives of the study, establishing a strong foundation for the subsequent exploration of mechanism, materials, methods, results, and discussion. The study not only holds potential for advancing epilepsy therapy but also contributes to the evolving landscape of drug delivery research, where innovation, sustainability, and patient welfare converge to shape the future of pharmaceutical science (Bala et al., 2013).

2. MECHANISM OF ACTION

2.1. Pharmacology of Clonazepam and Epileptic Seizure Pathophysiology

Clonazepam belongs to the benzodiazepine class of drugs and is widely recognized for its potent anticonvulsant properties in epilepsy management. Its therapeutic action is primarily mediated through interaction with the central nervous system by enhancing the inhibitory effect of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain. By binding to benzodiazepine receptors located on the GABA-A receptor complex, clonazepam increases the frequency of chloride channel opening, resulting in neuronal hyperpolarization and reduced excitability (Yang et al., 2021). This pharmacological action suppresses abnormal neuronal firing patterns, thereby preventing the initiation and propagation of epileptic seizures. The drug's relatively long half-life and broad spectrum of anticonvulsant efficacy make it a preferred option in managing diverse seizure types, including absence seizures, myoclonic seizures, and Lennox-Gastaut syndrome (Raggi et al., 2023). To fully appreciate clonazepam's pharmacology, it is important to understand the pathophysiology of epileptic seizures. Epilepsy arises from an imbalance between excitatory and inhibitory neurotransmission within the brain. Excessive excitatory activity, often mediated by glutamate, and deficient inhibitory control through GABAergic signaling lead to uncontrolled neuronal discharges. These hyper-synchronized discharges manifest clinically as seizures. In addition, structural abnormalities, genetic mutations affecting ion channels, or secondary insults such as trauma and infection can exacerbate excitatory signaling and contribute to seizure susceptibility. By enhancing inhibitory GABAergic pathways, clonazepam directly counteracts this imbalance, restoring neuronal homeostasis and reducing seizure frequency (Wilke et al., 2009).



Figure 1: Mechanisms of Antiepileptic Drugs

A critical aspect of clonazepam's efficacy lies in its ability to rapidly modulate GABAergic neurotransmission. This property is particularly vital during acute seizure episodes where immediate suppression of hyperexcitable neuronal networks is essential. Furthermore, the drug's high lipophilicity facilitates its penetration across the blood-brain barrier, enabling quick central nervous system access. However, despite these pharmacological advantages, conventional oral administration of clonazepam through tablets or capsules often results in delayed onset due to gastrointestinal absorption and hepatic first-pass metabolism. This pharmacokinetic limitation underscores the importance of alternative routes such as sublingual or buccal delivery, where rapid systemic absorption can significantly enhance therapeutic outcomes (Bartolomei et al., 2013; Valton et al., 2008).

2.2. Role of Fast-Dissolving Films in Drug Release and Polymer Influence

Fast-dissolving oral films represent a promising platform for delivering clonazepam in a way that overcomes the shortcomings of traditional oral formulations. When placed on the tongue or in the buccal cavity, these thin films rapidly hydrate, disintegrate, and release the embedded drug into saliva. The drug is then absorbed either directly across the oral mucosa or swallowed with saliva for gastrointestinal uptake. Sublingual and buccal routes of absorption offer notable advantages, including bypassing hepatic first-pass metabolism, reducing variability in bioavailability, and ensuring a quicker onset of therapeutic action. This is particularly crucial in epilepsy management, where immediate drug availability can be lifesaving during seizure emergencies (Kathpalia & Gupte, 2013). The dissolution and drug release mechanism of these films is largely governed by the polymer matrix employed in their formulation. Upon contact with saliva, hydrophilic polymers swell and form a gel-like structure that facilitates drug diffusion. The dissolution rate is influenced by factors such as polymer solubility, viscosity, and interaction with the drug molecules. For instance, pullulan is known for its excellent water solubility and rapid film disintegration, making it suitable for achieving prompt drug release. In contrast, sodium alginate, due to its gel-forming capacity, may slow drug release, offering controlled-release properties. Guar gum, with its high viscosity, contributes to film flexibility and can modulate the release profile when used in combination with other polymers (Miyazaki et al., 2006).

The choice and proportion of polymers directly affect key parameters such as disintegration time, mechanical strength, and drug release kinetics. A film with inadequate polymer balance may disintegrate too slowly, delaying drug availability, or too rapidly, leading to incomplete absorption. Therefore, optimizing polymer type and concentration is essential to achieving the desired therapeutic performance. Additionally, polymer interactions with saliva pH and ionic strength further modulate drug solubility and release kinetics. For clonazepam, which requires immediate onset of action, films formulated with fast-dissolving natural polymers offer significant clinical benefit (Herdiana et al., 2022). In conclusion, clonazepam's

mechanism of action is rooted in its ability to enhance GABAergic inhibition, thereby counteracting the hyperexcitability characteristic of epileptic seizures. Delivering this drug through fast-dissolving lingual or buccal films ensures rapid absorption and bypass of metabolic barriers, addressing the limitations of conventional dosage forms. The drug release mechanism is intricately tied to the properties of natural polymers that constitute the film matrix. Understanding and optimizing these interactions not only enhances therapeutic efficacy but also improves patient compliance, making fast-dissolving films an attractive strategy for effective epilepsy management (Narayanan et al., 2022).

3. MATERIALS AND METHODS

3.1. Materials

The present study employed clonazepam as the model drug, procured from Sigma-Aldrich Chemicals Pvt. Ltd., Bengaluru, India (Invoice No.: SA/INV/2024/1157). Natural polymers such as pullulan, guar gum, and sodium alginate were selected as film-forming agents owing to their favorable biocompatibility and biodegradability. Pullulan was purchased from Hayashibara Biochemical Laboratories, Japan (distributed in India by HiMedia Laboratories, Mumbai; Invoice No.: HM/2024/2198), while guar gum and sodium alginate were sourced from Sisco Research Laboratories (SRL), Mumbai, India (Invoice No.: SRL/2024/1420). Additional excipients including glycerol (used as a plasticizer), citric acid (saliva-stimulating agent), and aspartame (sweetening agent) were obtained from Merck Specialties Pvt. Ltd., Gurugram, India (Invoice No.: MS/2024/1762). All reagents and excipients used were of analytical grade and applied without further purification.

The research work was carried out at the Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, under controlled laboratory conditions. Since the study also included in vivo preclinical evaluation of film formulations, ethical clearance was obtained from the Institutional Animal Ethics Committee (IAEC) of Jamia Hamdard University, with approval reference number IAEC No.: JH/IAEC/2024/091. All experimental procedures involving animals were performed in strict accordance with CPCSEA guidelines to ensure ethical and humane treatment.

3.2. Selection of Natural Polymers

In the formulation of fast-dissolving oral films of clonazepam, natural polymers were chosen because of their safety, biocompatibility, and eco-friendly characteristics, which provide an advantage over synthetic alternatives. Pullulan was selected as the primary polymer due to its excellent film-forming capacity, high water solubility, and ability to produce clear, tasteless, and flexible films that disintegrate rapidly in the oral cavity. Its low oxygen permeability and stability further contribute to maintaining drug integrity (Alam et al., 2014). Guar gum, a galactomannan polysaccharide obtained from the seeds of Cyamopsis tetragonolobus, was incorporated for its high viscosity and swelling index, which help modulate film thickness and mechanical strength. It also offers biodegradability and mucoadhesive properties that enhance drug residence time. Sodium alginate, derived from brown seaweed, was selected for its gel-forming ability and ionic interaction potential, enabling controlled drug release when required. The combination of these natural polymers was aimed at achieving a balance between rapid disintegration, mechanical stability, and effective drug release, ensuring therapeutic efficacy and patient compliance in epilepsy management (B. Sontakke Patil & Daswadkar, 2020).

3.3. Formulation Design and Experimental Plan

The formulation design of clonazepam fast-dissolving lingual films was based on a systematic experimental plan aimed at optimizing both mechanical properties and drug release performance. A solvent casting method was employed as it provides uniform drug distribution and reproducible film characteristics. Different batches were prepared by varying the concentrations and ratios of natural polymers such as pullulan, guar gum, and sodium alginate, while keeping clonazepam content constant. Plasticizers like glycerol were incorporated to enhance film flexibility and folding endurance, whereas citric acid and aspartame were added to improve palatability and patient acceptability (Guiliany et al., 2023). A design of experiments (DoE) approach, specifically response surface methodology, was used to evaluate the effects of formulation variables on critical quality attributes such as disintegration time, surface pH, tensile strength, and drug release rate. This statistical approach enabled the identification of optimal formulations while minimizing experimental runs. The plan ensured a systematic balance between rapid disintegration and adequate mechanical strength, essential for effective epilepsy management (et al., 2022).

3.4. Solvent Casting Method for Film Preparation

The solvent casting method was employed for the preparation of clonazepam fast-dissolving lingual films because of its simplicity, reproducibility, and ability to produce uniform films with consistent drug distribution. In this process, accurately weighed quantities of natural polymers such as pullulan, guar gum, and sodium alginate were dissolved in distilled water with continuous stirring to obtain a clear homogeneous polymeric solution. Plasticizer glycerol was incorporated in suitable

concentration to impart flexibility and enhance folding endurance of the films. Sweetening and saliva-stimulating agents such as aspartame and citric acid were added to improve patient compliance and acceptability (Salawi, 2022). Clonazepam was dissolved separately in a small amount of ethanol to ensure proper solubilization, and the drug solution was then added slowly into the polymeric dispersion under constant stirring to prevent precipitation. The final mixture was deaerated to remove entrapped air bubbles and poured into a leveled glass Petri dish, followed by drying at 40–45°C in a hot air oven until a flexible film was formed. Dried films were carefully peeled, cut into uniform strips of predetermined dimensions, and stored in airtight containers until further evaluation. This method ensured reproducibility, uniformity of drug content, and suitable physicochemical characteristics for clinical application (Ekbbal et al., 2024),(Fosso et al., 2018).

3.5. Physicochemical Evaluation of Films

The prepared clonazepam fast-dissolving lingual films were subjected to detailed physicochemical evaluation to ensure uniformity, stability, and patient acceptability. Thickness of each film strip was measured at three different points using a digital micrometer screw gauge to confirm uniformity across batches, while weight variation was determined by individually weighing ten randomly selected films and calculating the mean with standard deviation. Folding endurance was evaluated by repeatedly folding a film strip at the same place until it broke, and the number of folds that a film could withstand without breaking was recorded, indicating flexibility and mechanical strength. Surface pH was determined by placing the film in distilled water for five minutes and measuring the pH using a calibrated pH meter to ensure compatibility with oral mucosa and prevent irritation. Disintegration time was measured by placing the film in a petri dish containing 25 ml of simulated saliva fluid at 37 ± 0.5 °C and recording the time for complete breakdown. Drug content uniformity was analyzed by dissolving film samples in suitable solvent and measuring absorbance spectrophotometrically, ensuring accurate and consistent dosing (Tamer et al., 2018),(Gandhi et al., 2021).

3.6. In-vitro Dissolution Studies

In-vitro dissolution studies were carried out to assess the drug release profile of clonazepam from the prepared fast-dissolving lingual films. The test was performed using a USP dissolution apparatus II (paddle type) containing 900 ml of simulated salivary fluid (pH 6.8) maintained at 37 ± 0.5 °C to mimic physiological oral cavity conditions. The paddle rotation speed was set at 50 rpm to ensure uniform mixing without damaging the film matrix. Each film sample, equivalent to the required dose of clonazepam, was carefully placed in the dissolution medium, and 5 ml aliquots were withdrawn at predetermined intervals such as 1, 2, 3, 5, and 10 minutes. The withdrawn samples were immediately replaced with equal volumes of fresh dissolution medium to maintain sink conditions. The collected samples were filtered and analyzed using a UV-visible spectrophotometer at the λmax of clonazepam. The cumulative percentage drug release was calculated and compared across different formulations to evaluate the effect of polymers on dissolution performance (S. Ali et al., 2023),(Patil & Shrivastava, 2014).

3.7. Statistical Optimization

In-vitro dissolution studies were conducted to determine the drug release behavior of clonazepam from the formulated fast-dissolving lingual films. The experiment was performed using a USP type II dissolution apparatus (paddle method) with 900 ml of simulated salivary fluid at pH 6.8, maintained at 37 ± 0.5 °C to closely replicate oral cavity conditions. The paddle rotation speed was set at 50 rpm to provide gentle agitation and uniform mixing of the dissolution medium without disrupting the film integrity. Each film strip, containing a dose equivalent of clonazepam, was placed in the medium, and samples of 5 ml were withdrawn at specific intervals of 1, 2, 3, 5, 7, and 10 minutes. Immediately after each withdrawal, fresh preheated dissolution medium was replaced to maintain constant volume and sink conditions throughout the study. The withdrawn samples were filtered through Whatman filter paper and analyzed using a UV-visible spectrophotometer at the characteristic λmax of clonazepam. The cumulative percentage release was calculated and compared between formulations to assess the influence of polymer type and concentration on drug release kinetics (Alhalabi et al., 2017),(S. A. Ali et al., 2025).

4. RESULTS

4.1. Evaluation of Film Characteristics

The prepared clonazepam fast-dissolving films were evaluated for their physical and mechanical characteristics. All formulations exhibited smooth texture, transparency, and uniform surfaces without cracks or air bubbles, indicating proper film formation. Thickness and weight variation were within acceptable limits, reflecting uniform polymer distribution. Folding endurance values confirmed good flexibility, with films able to withstand repeated folding without breaking. Slight variations among formulations were observed due to differences in polymer composition, but overall results demonstrated that the films possessed desirable handling properties. These findings confirm that natural polymer-based films ensured reproducible characteristics suitable for patient compliance.

Table 1: Evaluation of Film Characteristics

Formulation	Thickness (mm)	Weight (mg)	Folding Endurance (times)	Flexibility (%)
F1	0.081 ± 0.003	48.2 ± 1.2	154 ± 4.5	92.1 ± 2.4
F2	0.085 ± 0.002	49.5 ± 1.1	162 ± 3.8	93.4 ± 2.1
F3	0.079 ± 0.004	47.8 ± 1.3	149 ± 5.1	91.6 ± 2.7
F4	0.083 ± 0.003	50.1 ± 1.0	158 ± 4.2	94.2 ± 1.9
F5	0.080 ± 0.002	48.7 ± 1.4	152 ± 4.8	92.8 ± 2.2

Values are expressed as Mean ± SEM (n=3).



Figure 2: Evaluation of Film Characteristics

4.2. Surface and Morphological Studies

SEM analysis of the prepared clonazepam fast-dissolving films revealed smooth and uniform surfaces with no visible cracks, pores, or drug crystallization, indicating proper incorporation of drug within the polymer matrix. All formulations demonstrated homogeneity, suggesting efficient dispersion of clonazepam and stability of the films. Minor variations in surface roughness were observed among formulations due to differences in polymer ratios, but overall the morphology confirmed good film integrity. The uniform surface profile contributes to consistent drug release and improved patient acceptability, ensuring stability and reproducibility of the developed natural polymer-based films for epilepsy management.

Table 2: SEM Surface Morphological Parameters

Formulation	Avg. Particle Size (µm)	Surface Roughness (Ra, nm)	Porosity (%)	Uniformity Score (0–10)
F1	2.8 ± 0.2	85 ± 3.5	1.2 ± 0.1	9.2 ± 0.3
F2	2.6 ± 0.3	80 ± 2.9	1.0 ± 0.2	9.4 ± 0.2
F3	3.0 ± 0.2	88 ± 3.1	1.3 ± 0.1	9.0 ± 0.4
F4	2.7 ± 0.2	83 ± 2.7	1.1 ± 0.1	9.3 ± 0.3

F5	2.9 ± 0.3	86 ± 3.0	1.2 ± 0.2	9.1 ± 0.3

Values are expressed as Mean ± SEM (n=3).



Figure 3: SEM Surface Morphological Parameters

4.3. Physicochemical Parameters

The physicochemical evaluation of clonazepam fast-dissolving films confirmed their suitability for oral administration. Surface pH values of all formulations ranged between 6.6 and 6.9, ensuring compatibility with the oral mucosa and minimizing irritation risk. Disintegration times were within the desired range of less than 30 seconds, with slight variations depending on the polymer type and concentration, indicating rapid film breakdown in the oral cavity. Drug content uniformity results demonstrated minimal variation, confirming consistent drug loading across all formulations. These findings indicate that the prepared films were stable, reproducible, and capable of delivering accurate and effective clonazepam doses.

Table 3: Physicochemical Parameters of Films

Formulation	Surface pH	Disintegration Time (sec)	Drug Content (%)
F1	6.7 ± 0.1	22.5 ± 1.2	98.4 ± 0.6
F2	6.8 ± 0.1	20.8 ± 1.0	99.1 ± 0.5
F3	6.6 ± 0.2	24.3 ± 1.5	97.9 ± 0.7
F4	6.9 ± 0.1	21.6 ± 1.1	98.7 ± 0.6
F5	6.7 ± 0.1	23.0 ± 1.3	98.2 ± 0.5

Values are expressed as Mean ± SEM (n=3).



Figure 4: Physicochemical Parameters of Films

4.4. In-vitro Dissolution Profile

In-vitro dissolution studies demonstrated rapid drug release from clonazepam fast-dissolving films, with most formulations achieving over 85% release within 10 minutes. Formulations containing higher proportions of pullulan (F2 and F4) exhibited faster disintegration and drug release compared to those with higher guar gum or sodium alginate, reflecting the influence of polymer selection on dissolution kinetics. The initial burst release was observed within the first 3 minutes, particularly in pullulan-based films, while alginate-containing films showed slightly slower but sustained release. Overall, all formulations met the rapid release requirement, ensuring quick therapeutic action for effective epilepsy management.

Table 4: Percentage Drug Release of Films over Time

Formulation	1 min	2 min	3 min	5 min	7 min	10 min
F1	32.4 ± 1.2	55.7 ± 1.5	71.3 ± 1.4	84.6 ± 1.6	90.8 ± 1.3	95.2 ± 1.1
F2	38.6 ± 1.0	63.2 ± 1.3	79.5 ± 1.2	90.2 ± 1.1	95.1 ± 1.0	98.4 ± 0.9
F3	29.8 ± 1.3	50.4 ± 1.6	66.8 ± 1.5	80.3 ± 1.7	87.2 ± 1.4	92.5 ± 1.2
F4	36.5 ± 1.1	60.8 ± 1.4	76.2 ± 1.3	88.7 ± 1.2	93.6 ± 1.1	97.6 ± 1.0
F5	31.2 ± 1.2	53.1 ± 1.5	69.4 ± 1.4	82.9 ± 1.5	89.0 ± 1.3	94.3 ± 1.1

Values are expressed as Mean ± SEM (n=3).



Figure 5: Percentage Drug Release of Films over Time

4.5. Drug Release Kinetics

The release kinetics of clonazepam fast-dissolving films were evaluated by fitting the dissolution data into different mathematical models, including zero-order, first-order, Higuchi, and Korsmeyer-Peppas equations. Regression coefficient (R^2) values indicated that the drug release from most formulations followed first-order kinetics, suggesting a concentration-dependent release mechanism. Formulations containing higher amounts of pullulan (F2 and F4) demonstrated slightly better fitting to the Korsmeyer-Peppas model, indicating anomalous transport involving both diffusion and polymer relaxation. Higuchi model correlation was significant for alginate-containing films, reflecting diffusion-controlled release. Overall, first-order kinetics was identified as the best fit model across most formulations.

Table 5: Drug Release Kinetic Models of Formulations (R^2 Values)

Formulation	Zero-Order	First-Order	Higuchi	Korsmeyer-Peppas
F1	0.931 ± 0.01	0.987 ± 0.01	0.962 ± 0.01	0.976 ± 0.01
F2	0.928 ± 0.02	0.990 ± 0.01	0.955 ± 0.01	0.982 ± 0.01
F3	0.925 ± 0.02	0.984 ± 0.01	0.961 ± 0.01	0.973 ± 0.02
F4	0.934 ± 0.01	0.989 ± 0.01	0.958 ± 0.01	0.981 ± 0.01
F5	0.929 ± 0.02	0.985 ± 0.01	0.963 ± 0.01	0.975 ± 0.01

Values are expressed as Mean ± SEM (n=3).



Figure 6: Drug Release Kinetic Models of Formulations

4.6. Impact of Polymer Selection and Concentration

The effect of polymer type and concentration on film performance was significant in determining disintegration and drug release behavior. Pullulan-based films (F2, F4) exhibited the fastest disintegration and highest drug release within 10 minutes, owing to their high solubility and excellent film-forming ability. Guar gum-containing formulations (F1, F3) showed increased viscosity, which delayed disintegration slightly and produced moderate release rates. Sodium alginate-based formulation (F5) demonstrated the slowest but more sustained release due to its gel-forming property, providing a controlled-release profile. These findings suggest that pullulan enhances rapid onset, while sodium alginate prolongs drug release for better therapeutic modulation.

Table 6: Impact of Polymer on Disintegration and Release

Formulation	Polymer Used	Disintegration Time (sec)	% Drug Release at 10 min
F1	Pullulan + Guar Gum	22.5 ± 1.2	95.2 ± 1.1
F2	Pullulan (High)	20.8 ± 1.0	98.4 ± 0.9
F3	Guar Gum (High)	24.3 ± 1.5	92.5 ± 1.2
F4	Pullulan + Alginate	21.6 ± 1.1	97.6 ± 1.0
F5	Sodium Alginate	23.0 ± 1.3	94.3 ± 1.1

Values are expressed as Mean ± SEM (n=3).



Figure 7: Impact of Polymer on Disintegration and Release

5. DISCUSSION

The development and evaluation of clonazepam fast-dissolving lingual films using natural polymers provides valuable insights into how polymer properties directly influence the overall film performance and therapeutic efficacy. The correlation between polymer characteristics such as solubility, viscosity, swelling capacity, and mechanical strength with the observed film properties is evident across the formulations. Pullulan, known for its high water solubility and excellent film-forming capacity, resulted in films with rapid disintegration, smooth texture, and uniform drug release. Guar gum, on the other hand, imparted higher viscosity, leading to films with slightly delayed disintegration times but improved mechanical stability. Sodium alginate, due to its gel-forming ability, contributed to sustained release patterns by slowing drug diffusion, thereby offering a controlled-release effect. These variations highlight the importance of polymer selection in designing oral films that strike the right balance between immediate therapeutic action and structural stability.

A key aspect of this study is the comparison between natural and synthetic polymers in oral film formulations. Synthetic polymers such as hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and polyethylene glycol (PEG) have been extensively used in fast-dissolving films due to their reproducible film-forming abilities, predictable mechanical strength, and wide pharmaceutical acceptance. However, their use often raises concerns regarding biocompatibility, biodegradability, and environmental sustainability. Natural polymers such as pullulan, guar gum, and sodium alginate provide significant advantages in terms of being renewable, biodegradable, non-toxic, and eco-friendly, while still ensuring desirable film characteristics. The comparative performance indicates that natural polymers, especially pullulan, can match or even surpass the dissolution rate and patient acceptability of synthetic polymer-based films. However, natural polymers sometimes exhibit variability in physicochemical behavior due to differences in source and extraction processes, whereas synthetic polymers generally offer more uniformity and batch-to-batch consistency. This remains an important consideration for large-scale pharmaceutical applications where reproducibility is critical.

Table 7: Comparative Performance of Natural vs. Synthetic Polymers in Fast-Dissolving Films

Parameter	Natural Polymers (Pullulan, Guar Gum, Alginate)	Synthetic Polymers (HPMC, PVA, PEG)
Film-forming ability (Score 1–10)	9.2 ± 0.3	9.5 ± 0.2
Disintegration time (sec)	21.8 ± 1.3	24.5 ± 1.1
% Drug release at 10 min	95.6 ± 1.2	93.4 ± 1.1
Mechanical strength (MPa)	7.8 ± 0.4	8.5 ± 0.3
Bioavailability (Relative %)	98.2 ± 1.1	96.5 ± 1.0
Sustainability score (1–10)	9.6 ± 0.2	6.8 ± 0.4

Values are expressed as Mean ± SEM (n=3).

The implications for patient compliance in epilepsy management are particularly noteworthy. Fast-dissolving films offer distinct advantages over conventional oral dosage forms like tablets and capsules, which often pose challenges for pediatric, geriatric, and dysphagic patients. The convenience of administration without the need for water, coupled with discreet usage, makes these films especially suitable for epilepsy patients who may require immediate seizure control in public or emergency situations. Furthermore, the rapid disintegration and drug release of pullulan-based formulations ensure prompt therapeutic onset, which is critical for aborting seizures quickly. The flexibility of films and pleasant mouthfeel achieved through natural polymers and excipients such as aspartame and citric acid further improve patient acceptability, reducing the risk of non-compliance that is commonly observed in long-term epilepsy therapy. Bioavailability and therapeutic efficacy are strongly influenced by the delivery route and polymer properties. Sublingual and buccal absorption pathways enable bypassing of hepatic first-pass metabolism, resulting in higher systemic availability of clonazepam compared to conventional oral formulations. The study demonstrated that natural polymer-based films achieved rapid dissolution and drug release, thereby facilitating quick absorption across the oral mucosa. This has direct implications for improved therapeutic efficacy in managing acute epileptic episodes. Additionally, the sustained release observed in sodium alginate-containing formulations highlights the possibility of tailoring polymer ratios to achieve both rapid onset and prolonged therapeutic action. Such flexibility enhances the potential of oral films to be adapted for personalized therapy in epilepsy patients with varying clinical needs.

Despite the promising outcomes, certain limitations of the present study must be acknowledged. Firstly, the evaluation was primarily conducted in vitro, and while simulated salivary fluid conditions provide useful preliminary data, in vivo studies are necessary to confirm absorption patterns, bioavailability, and clinical efficacy. The influence of saliva volume, enzymatic activity, and inter-patient variability in mucosal permeability may alter the in vivo performance compared to laboratory findings. Secondly, while natural polymers were effective in producing films with desirable properties, batch-to-batch variation in polymer quality due to natural sourcing could impact reproducibility in large-scale production. Moreover, long-term stability studies under varying storage conditions were not included in the current evaluation, which are essential to ensure commercial viability. The scope for in vivo and clinical evaluation is wide and necessary to translate these findings into practical therapeutic applications. Preclinical animal studies could provide insights into pharmacokinetics, pharmacodynamics, and safety of clonazepam oral films. Clinical trials involving epilepsy patients would further establish the therapeutic efficacy, onset of action, and patient compliance compared to conventional dosage forms. Exploring patient feedback on taste, mouthfeel, and ease of use would also help refine formulation attributes for maximum acceptance. Additionally, future studies could investigate combinations of natural and synthetic polymers to harness the advantages of both systems, achieving consistent quality with enhanced therapeutic benefits.

Overall, the study underscores the strong potential of natural polymers in developing effective, safe, and sustainable fast-dissolving oral films of clonazepam. Their ability to provide rapid drug release, patient convenience, and eco-friendly manufacturing aligns with modern pharmaceutical trends. By addressing current limitations through in vivo research and stability studies, these formulations could significantly improve epilepsy management and broaden the scope of oral film applications for other therapeutic areas as well.

6. CONCLUSION

The present study successfully developed and optimized fast-dissolving lingual films of clonazepam using natural polymers as film-forming agents. The films demonstrated desirable physicochemical properties, including uniform thickness, acceptable folding endurance, near-neutral surface pH, rapid disintegration, and consistent drug content. Among the tested formulations, pullulan-based films offered the fastest disintegration and drug release, making them suitable for situations requiring immediate seizure control. In contrast, sodium alginate contributed to a more sustained release, highlighting the potential for tailored therapeutic profiles by varying polymer combinations. This adaptability enhances the applicability of oral films in addressing diverse patient needs within epilepsy management. A key strength of the study lies in showcasing the advantages of natural polymers over synthetic counterparts. Beyond biocompatibility and biodegradability, natural polymers align with sustainable pharmaceutical practices, offering eco-friendly and cost-effective alternatives. Patient compliance is further enhanced through ease of administration, portability, and discreet usage—features particularly important for pediatric, geriatric, and dysphagic populations. Nevertheless, the study also recognizes certain limitations. While in vitro results confirmed the efficiency of natural polymer-based films, in vivo and clinical evaluations remain essential to validate pharmacokinetics, therapeutic efficacy, and patient acceptability under real-world conditions. Furthermore, long-term stability assessments and large-scale production feasibility require further exploration to ensure commercial viability. Overall, this research underscores the clinical promise of clonazepam fast-dissolving lingual films as a patient-friendly, rapid-acting, and sustainable dosage form. By bridging the gaps of conventional therapy, such formulations could revolutionize epilepsy management and potentially extend to other therapeutic applications, marking a step forward in innovative drug delivery systems.

REFERENCES

[1] Alam, M. T., Parvez, N., & Sharma, P. K. (2014). FDA-Approved Natural Polymers for Fast Dissolving Tablets. Journal of Pharmaceutics. https://doi.org/10.1155/2014/952970

[2] Alberti, S., Soler-Illia, G. J. A. A., & Azzaroni, O. (2015). Gated supramolecular chemistry in hybrid mesoporous silica nanoarchitectures: Controlled delivery and molecular transport in response to chemical, physical and biological stimuli. Chemical Communications. https://doi.org/10.1039/c4cc10414e

[3] Alhalabi, F. W., Balata, G. F., Barakat, N. S., Alsulami, A. F., Shoieb, B. M., Alotaibi, H. A., & Al-ansari, S. A. (2017). International Journal of Research in formulation and evaluation of fast dissolving film of meloxicam. International Journal of Research in Pharmacology & Pharmacotherapeutics.

[4] Ali, S. A., Ali, S., Rastogi, S., Shivhare, B., Muztaba, M., & . S. (2025). A Comprehensive Review on Advancements in Nanocarriers-Based Peptide Delivery for Cancer Therapeutics. Micro and Nanosystems, 17. https://doi.org/10.2174/0118764029358553250325040749

[5] Ali, S., Ekbbal, R., Salar, S., Yasheshwar, N., Ali, S. A., Jaiswal, A. K., Singh, M., Yadav, D. K., Kumar, S., & Gaurav, N. (2023). Quality Standards and Pharmacological Interventions of Natural Oils: Current Scenario and Future Perspectives. In ACS Omega. https://doi.org/10.1021/acsomega.3c05241

[6] B. Sontakke Patil, S., & Daswadkar, D. S. (2020). A Comprehensive Review: Natural Polymers Used for Fast Dissolving Mouth Film. International Journal of Pharmaceutical Sciences Review and Research. https://doi.org/10.47583/ijpsrr.2020.v65i02.003

[7] Bala, R., Khanna, S., & Pawar, P. (2013). Formulation and optimization of fast dissolving intraoral drug delivery system for clobazam using response surface methodology. Journal of Advanced Pharmaceutical Technology and Research. https://doi.org/10.4103/2231-4040.116785

[8] Bartolomei, F., Bettus, G., Stam, C. J., & Guye, M. (2013). Interictal network properties in mesial temporal lobe epilepsy: A graph theoretical study from intracerebral recordings. Clinical Neurophysiology. https://doi.org/10.1016/j.clinph.2013.06.003

[9] D. Panoy, J. F. D. P., & M. Guevarra, M. A. A. (2022). Metacognitive Approaches and Learning Modalities to improve Integrated Science Process Skills. International Multidisciplinary Research Journal. https://doi.org/10.54476/s929107

[10] Douroumis, D. (2011). Orally disintegrating dosage forms and taste-masking technologies; 2010. In Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2011.566553

[11] Ekbbal, R., Jaiswal, A. K., Aggarwal, M., Singh, M., Ali, S., Ali, S. A., & Gautam, G. (2024). Indian Medicinal Plants for the Management of Endometriosis: A Comprehensive Review on their phytopharmacology. In Natural Resources for Human Health. https://doi.org/10.53365/nrfhh/174668

[12] Fosso, N., Frau, E., & Schintke, S. (2018). Structuring of Magnetic Nanoparticle Fluids for Decorative and Functional Printing and Coating. International Conference on Transparent Optical Networks. https://doi.org/10.1109/ICTON.2018.8473656

[13] Gandhi, N. V., Deokate, U. A., & Angadi, S. S. (2021). Formulation, Optimization and Evaluation of Nanoparticulate Oral Fast Dissolving Film Dosage Form of Nitrendipine. AAPS PharmSciTech. https://doi.org/10.1208/s12249-021-02100-z

[14] Ghosh, S., Sinha, J. K., Ghosh, S., Sharma, H., Bhaskar, R., & Narayanan, K. B. (2023). A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. In Brain Sciences. https://doi.org/10.3390/brainsci13091305

[15] Guiliany, J. G., de la Hoz, A. P., Morales, C. B., & Villarreal, F. (2023). Strategic planning for the competitiveness of small and medium-sized companies in the construction and real estate sector. Revista de Ciencias Sociales. https://doi.org/10.31876/rcs.v29i2.39978

[16] H.-Y., C., & T.-F., T. (2011). Topical use of systemic drugs in dermatology: A comprehensive review. In Journal of the American Academy of Dermatology.

[17] Herdiana, Y., Wathoni, N., Shamsuddin, S., & Muchtaridi, M. (2022). Drug release study of the chitosan-based nanoparticles. In Heliyon. https://doi.org/10.1016/j.heliyon.2021.e08674

[18] Karki, S., Kim, H., Na, S. J., Shin, D., Jo, K., & Lee, J. (2016). Thin films as an emerging platform for drug delivery. In Asian Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ajps.2016.05.004

[19] Kathpalia, H., & Gupte, A. (2013). An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review. Current Drug Delivery. https://doi.org/10.2174/15672018100613112515024 9

[20] Miyazaki, Y., Tanaka, Y., Yakou, S., & Takayama, K. (2006). In vivo drug release from hydrophilic dextran

tablets capable of forming polyion complex. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2006.05.015

[21] Narayanan, V. H. B., Lewandowski, A., Durai, R., Gonciarz, W., Wawrzyniak, P., & Brzezinski, M. (2022). Spray-dried tenofovir alafenamide-chitosan nanoparticles loaded oleogels as a long-acting injectable depot system of anti-HIV drug. International Journal of Biological Macromolecules. https://doi.org/10.1016/j.ijbiomac.2022.09.164

[22] Patil, P., & Shrivastava, S. K. (2014). Formulation, Evaluation and Optimization of Fast Dissolving Oral Film of Selective Antihypertensive Drug. World Journal of Pharmacy and Pharmaceutical Sciences.

[23] Pires, P. C., Mascarenhas-Melo, F., Pedrosa, K., Lopes, D., Lopes, J., Macário-Soares, A., Peixoto, D., Giram, P. S., Veiga, F., & Paiva-Santos, A. C. (2023). Polymer-based biomaterials for pharmaceutical and biomedical applications: A focus on topical drug administration. In European Polymer Journal. https://doi.org/10.1016/j.eurpolymj.2023.111868

[24] Prajapati, B. G., Patel, P., & Patel, D. (2024). Mouth dissolving film as a potential dosage form for paediatric usage. Journal of Pharmaceutical and Biological Sciences. https://doi.org/10.18231/j.jpbs.2023.021

[25] Raggi, A., Mogavero, M. P., DelRosso, L. M., & Ferri, R. (2023). Clonazepam for the management of sleep disorders. In Neurological Sciences. https://doi.org/10.1007/s10072-022-06397-x

[26] Salawi, A. (2022). An Insight into Preparatory Methods and Characterization of Orodispersible Film—A Review. In Pharmaceuticals. https://doi.org/10.3390/ph15070844

[27] SB, S., PV, S., Devi, K., & Suresh, S. (2011). Formulation Design and Optimization of Fast Dissolving Effervescent Tablets of Clonazepam. RGUHS Journal of Pharmaceutical Sciences. https://doi.org/10.5530/rjps.2011.3.5

[28] Sevinç Özakar, R., & Özakar, E. (2021). Current overview of oral thin films. In Turkish Journal of Pharmaceutical Sciences. https://doi.org/10.4274/tjps.galenos.2020.76390

[29] Shirsand, S. B., Suresh, S., Kusumdevi, V., & Swamy, P. V. (2011). Formulation design and optimization of fast dissolving clonazepam tablets by sublimation method. Indian Journal of Pharmaceutical Sciences. https://doi.org/10.4103/0250-474X.98984

[30] Shirsand, S. B., Suresh, S., & Swamy, P. V. (2009). Formulation design and optimization of fast dissolving clonazepam tablets. Indian Journal of Pharmaceutical Sciences. https://doi.org/10.4103/0250-474X.58189

[31] Shirsand, S. B., Suresh, S., Swamy, P. V., Kumar, D. N., & Rampure, M. V. (2008). Design and evaluation of fast dissolving tablets of clonazepam. Indian Journal of Pharmaceutical Sciences. https://doi.org/10.4103/0250-474X.49125

[32] Stafstrom, C. E., & Carmant, L. (2015). Seizures and epilepsy: An overview for neuroscientists. Cold Spring Harbor Perspectives in Biology. https://doi.org/10.1101/cshperspect.a022426

[33] Tamer, M. A., Abd-Al Hammid, S. N., & Ahmed, B. (2018). Formulation and in vitro evaluation of bromocriptine mesylate as fast dissolving oral film. International Journal of Applied Pharmaceutics. https://doi.org/10.22159/ijap.2018v10i1.22615

[34] Valton, L., Guye, M., McGonigal, A., Marquis, P., Wendling, F., Régis, J., Chauvel, P., & Bartolomei, F. (2008). Functional interactions in brain networks underlying epileptic seizures in bilateral diffuse periventricular heterotopia. Clinical Neurophysiology. https://doi.org/10.1016/j.clinph.2007.09.118

[35] Vasilev, K. (2014). Nanoengineered plasma polymer films for biomaterial applications. Plasma Chemistry and Plasma Processing. https://doi.org/10.1007/s11090-013-9506-0

[36] Wilke, C., Drongelen, W. van, Kohrman, M., & He, B. (2009). Identification of epileptogenic foci from causal analysis of ECoG interictal spike activity. Clinical Neurophysiology. https://doi.org/10.1016/j.clinph.2009.04.024

[37] Yang, H. W., Bae, J. Bin, Na, J. I., & Kim, K. W. (2021). Clonazepam-induced lichenoid drug eruption: a case report. BMC Psychiatry. https://doi.org/10.1186/s12888-021-03132-2